Equitable Trust Co. Sells 15,075 Shares of Edwards Lifesciences Corporation $EW

Equitable Trust Co. trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 22.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,513 shares of the medical research company’s stock after selling 15,075 shares during the quarter. Equitable Trust Co.’s holdings in Edwards Lifesciences were worth $4,162,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. True Wealth Design LLC raised its position in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares in the last quarter. NewSquare Capital LLC increased its stake in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the period. Hantz Financial Services Inc. raised its holdings in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $79.88 on Monday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock has a market cap of $46.35 billion, a PE ratio of 43.65, a PEG ratio of 2.08 and a beta of 0.94. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a 50-day simple moving average of $82.80 and a two-hundred day simple moving average of $81.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Citigroup reissued a “buy” rating and set a $101.00 price target (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $90.00 to $100.00 in a research note on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 43,804 shares of company stock worth $3,699,082. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.